# INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

> **NCT01164163** · PHASE1 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 49 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** ruxolitinib phosphate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01164163
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2014-10
- **Final completion:** —
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01164163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01164163, "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01164163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*